keyword
MENU ▼
Read by QxMD icon Read
search

Journal of clinical oncology

keyword
https://www.readbyqxmd.com/read/29313062/art-or-science-an-evidence-based-approach-to-human-facial-beauty-a-quantitative-analysis-towards-an-informed-clinical-aesthetic-practice
#1
REVIEW
Harpal Harrar, Simon Myers, Ali M Ghanem
BACKGROUND: Patients often seek guidance from the aesthetic practitioners regarding treatments to enhance their 'beauty'. Is there a science behind the art of assessment and if so is it measurable? Through the centuries, this question has challenged scholars, artists and surgeons. AIMS AND OBJECTIVES: This study aims to undertake a review of the evidence behind quantitative facial measurements in assessing beauty to help the practitioner in everyday aesthetic practice...
January 8, 2018: Aesthetic Plastic Surgery
https://www.readbyqxmd.com/read/29303624/optimization-of-risk-stratification-in-localized-prostate-cancer
#2
Alicia Katherine Morgans
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
January 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29290918/laparoscopic-vs-open-complete-mesocolic-excision-with-central-vascular-ligation-for-colon-cancer-a-systematic-review-and-meta-analysis
#3
Ionut Negoi, Sorin Hostiuc, Ruxandra Irina Negoi, Mircea Beuran
AIM: To compare the effectiveness of laparoscopic complete mesocolic excision (CME) with central vascular ligation (L-CME) with its open (O-CME) counterpart. METHODS: We conducted an electronic search of the PubMed/MEDLINE, Excerpta Medica Database, Web of Science Core Collection, Cochrane Center Register of Controlled Trails, Cochrane Database of Systematic Reviews, SciELO, and Korean Journal databases from their inception until May 2017. We considered randomized controlled trials (RCTs) and controlled clinical trials (CCTs) that included patients with colonic cancer comparing L-CME and O-CME...
December 15, 2017: World Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29249246/-what-s-new-in-clinical-dermatology
#4
A Petit
In addition to continuous medical education, medical journals offer to dermatologists a huge variety of news that differ by their content, validity, originality and clinical relevance. I collected here various articles relative to clinical dermatology that have been published between September, 2016 and September, 2017. These papers have been chosen in the aim of reflecting such diversity. I just excluded, as far as possible, articles dealing with other issues that the reader will find further in this booklet (such as research, pediatric, instrumental, oncologic or therapeutic dermatology, or dermatology and internal medicine)...
December 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29246224/optimizing-clinical-and-organizational-practice-in-cancer-survivor-transitions-between-specialized-oncology-and-primary-care-teams-a-realist-evaluation-of-multiple-case-studies
#5
Dominique Tremblay, Catherine Prady, Karine Bilodeau, Nassera Touati, Maud-Christine Chouinard, Martin Fortin, Isabelle Gaboury, Jean Rodrigue, Marie-France L'Italien
BACKGROUND: Cancer is now viewed as a chronic disease, presenting challenges to follow-up and survivorship care. Models to shift from haphazard, suboptimal and fragmented episodes of care to an integrated cancer care continuum must be developed, tested and implemented. Numerous studies demonstrate improved care when follow-up is assured by both oncology and primary care providers rather than either group alone. However, there is little data on the roles assumed by specialized oncology teams and primary care providers and the extent to which they work together...
December 16, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/29242023/open-access-journal-policies-a-systematic-analysis-of-radiology-journals
#6
Anand Narayan, Katie Lobner, Jan Fritz
OBJECTIVE: The open access movement has pushed for greater access to scientific knowledge by expanding access to scientific journal articles. There is limited information about the extent to which open access policies have been adopted by radiology journals. We performed a systematic analysis to ascertain the proportion of radiology journals with open access options. MATERIALS AND METHODS: A search was performed with the assistance of a clinical informationist. Full and mixed English-language diagnostic and interventional radiology Web of Science journals (impact factors > 1...
December 11, 2017: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/29228640/comparison-of-primary-endpoints-between-publications-registries-and-protocols-of-phase-iii-cancer-clinical-trials
#7
Fei Liang, Xinmei Guo, Sheng Zhang, Hongxi Xue, Qiang Chen, Xichun Hu
Background: Decisions by leading journals to require trial registration and to make protocols of phase III randomized clinical trials (RCTs) publicly accessible were landmark events in clinical trial reporting. Materials and Methods: We identified phase III cancer RCTs published between 2013 and 2015 in New England Journal of Medicine (NEJM), The Lancet, The lancet Oncology, JAMA and Journal of Clinical Oncology (JCO). Results: We identified 345 reports of phase III RCTs of which 217 (62...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29216190/quality-of-reporting-in-oncology-phase-ii-trials-a-5-year-assessment-through-systematic-review
#8
Julien Langrand-Escure, Romain Rivoirard, Mathieu Oriol, Fabien Tinquaut, Chloé Rancoule, Frank Chauvin, Nicolas Magné, Aurélie Bourmaud
BACKGROUND: Phase II clinical trials are a cornerstone of the development in experimental treatments They work as a "filter" for phase III trials confirmation. Surprisingly the attrition ratio in Phase III trials in oncology is significantly higher than in any other medical specialty. This suggests phase II trials in oncology fail to achieve their goal. Objective The present study aims at estimating the quality of reporting in published oncology phase II clinical trials. DATA SOURCES: A literature review was conducted among all phase II and phase II/III clinical trials published during a 5-year period (2010-2015)...
2017: PloS One
https://www.readbyqxmd.com/read/29206554/front-line-treatment-options-for-chronic-phase-chronic-myeloid-leukemia
#9
Neil P Shah
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
December 5, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29168653/utilizing-biomarkers-in-colorectal-cancer-an-interview-with-ajay-goel
#10
Ajay Goel
Ajay Goel, PhD, is a Professor and Director, Center for Gastrointestinal Research, and Director, Center for Translational Genomics and Oncology, at the Baylor Scott & White Research Institute, Baylor University Medical Center in Dallas, Texas. Dr Goel has spent more than 20 years researching cancer and has been the lead author or contributor to over 240 scientific articles published in peer-reviewed international journals and several book chapters. He is also a primary inventor on more than 15 international patents aimed at developing various biomarkers for the diagnosis, prognosis and prediction of gastrointestinal cancers...
November 23, 2017: Future Oncology
https://www.readbyqxmd.com/read/29151366/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-76-85-edited-by-chinese-journal-of-cancer
#11
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology to promote cancer research and accelerate collaborations. In this article, 10 questions are presented as followed. Question 76. How to develop effective therapeutics for cancer cachexia? Question 77. How can we develop preclinical animal models to recapitulate clinical situations of cancer patients for more effective anti-cancer drug development? Question 78. How can we develop novel effective therapeutics for pancreatic cancer and hepatocellular carcinoma? Question 79...
November 20, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/29120964/analysis-of-survival-of-patients-treated-with-vemurafenib-ipilimumab-and-dabrafenib-for-advanced-skin-melanoma-in-daily-clinical-practice-real-world-data-retrospective-analysis-of-patients-treated-under-drug-reimbursement-programmes-in-poland-in-2013-2016
#12
Melania Brzozowska, Waldemar Wierzba, Andrzej Śliwczyński, Marcin Świerkowski, Piotr Potemski, Michał Marczak
Vemurafenib, ipilimumab and dabrafenib were registered for the treatment of advanced skin melanoma pursuant to the results of randomized phase III clinical trials. Real-world data on survival time for patients treated with those drugs in daily clinical practice are so far limited. Patients with advanced skin melanoma treated under reimbursement programmes (drug programmes), for which they were qualified pursuant to uniform inclusion criteria in force in all oncology centres in Poland. Data were obtained from the electronic databases of the national payer (NFZ) responsible for the implementation and monitoring of reimbursement (drug) programmes...
November 8, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29120700/basket-studies-redefining-clinical-trials-in-the-era-of-genome-driven-oncology
#13
Jessica J Tao, Alison M Schram, David M Hyman
Understanding a tumor's detailed molecular profile has become increasingly necessary to deliver the standard of care for patients with advanced cancer. Innovations in both tumor genomic sequencing technology and the development of drugs that target molecular alterations have fueled recent gains in genome-driven oncology care. "Basket studies," or histology-agnostic clinical trials in genomically selected patients, represent one important research tool to continue making progress in this field. We review key aspects of genome-driven oncology care, including the purpose and utility of basket studies, biostatistical considerations in trial design, genomic knowledge-base development, and patient matching and enrollment models, which are critical for translating our genomic knowledge into clinically meaningful outcomes...
November 8, 2017: Annual Review of Medicine
https://www.readbyqxmd.com/read/29109935/striking-balance-between-expedited-review-and-expecting-efficacious-anticancer-drug-and-biologics-an-ongoing-challenge
#14
Krishnan Vengadaragava Chary, Anita Ramesh
Objective: The objective of this study is to assess the postmarketing status: Efficacy and safety drugs and biologics related with cancer approved under expedited review. Methods: This observational, analytical study was carried between January and April 2016 by the Department of Pharmacology and Medical Oncology, Saveetha Medical College. Drugs approved under expedited review, fast-track status and its association with anti-cancer effects, postmarketing efficacy and safety, propensity to induce the second tumor was noted...
October 2017: Perspectives in Clinical Research
https://www.readbyqxmd.com/read/29092716/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-67-75-edited-by-chinese-journal-of-cancer
#15
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 9 more questions are presented as followed. Question 67. How could we overcome the resistance of hepatocellular carcinoma against chemotherapeutics? Question 68. Is pursuit of non-covalent small-molecule binders of RAS proteins viable as a strategy of cancer drug discovery? Question 69...
November 1, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/29077691/preclinical-mouse-solid-tumour-models-status-quo-challenges-and-perspectives
#16
REVIEW
Nicolas Gengenbacher, Mahak Singhal, Hellmut G Augustin
Oncology research in humans is limited to analytical and observational studies for obvious ethical reasons, with therapy-focused clinical trials being the one exception to this rule. Preclinical mouse tumour models therefore serve as an indispensable intermediate experimental model system bridging more reductionist in vitro research with human studies. Based on a systematic survey of preclinical mouse tumour studies published in eight scientific journals in 2016, this Analysis provides an overview of how contemporary preclinical mouse tumour biology research is pursued...
December 2017: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/29076867/patient-and-oncology-nurse-preferences-for-the-treatment-options-in-advanced-melanoma-a-discrete-choice-experiment
#17
Frank Xiaoqing Liu, Edward A Witt, Scot Ebbinghaus, Grace DiBonaventura Beyer, Enrique Basurto, Richard W Joseph
BACKGROUND: Understanding the perceptions of patients and oncology nurses about the relative importance of benefits and risks associated with newer treatments of advanced melanoma can help to inform clinical decision-making. OBJECTIVES: The aims of this study were to quantify and compare the views of patients and oncology nurses regarding the importance of attributes of treatments of advanced melanoma. METHODS: A discrete choice experiment (DCE) was conducted in US-based oncology nurses and patients diagnosed with advanced melanoma...
October 25, 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28974261/the-150-most-important-questions-in-cancer-research-and-clinical-oncology-series-questions-57-66-edited-by-chinese-journal-of-cancer
#18
EDITORIAL
(no author information available yet)
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 57. What are the major stresses that drive the formation, progression, and metastasis of a cancer? Question 58. What is the mechanism responsible for altering an acidic intracellular pH and a basic extracellular pH in normal tissue cells to a basic intracellular pH and an acidic extracellular pH in cancer cells, a fundamental and yet largely ignored phenomenon? Question 59...
October 3, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28973512/big-data-research-in-neurosurgery-a-critical-look-at-this-popular-new-study-design
#19
Chesney S Oravec, Mustafa Motiwala, Kevin Reed, Douglas Kondziolka, Fred G Barker, L Madison Michael, Paul Klimo
The use of "big data" in neurosurgical research has become increasingly popular. However, using this type of data comes with limitations. This study aimed to shed light on this new approach to clinical research. We compiled a list of commonly used databases that were not specifically created to study neurosurgical procedures, conditions, or diseases. Three North American journals were manually searched for articles published since 2000 utilizing these and other non-neurosurgery-specific databases. A number of data points per article were collected, tallied, and analyzed...
July 21, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28954288/two-by-two-factorial-cancer-treatment-trials-is-sufficient-attention-being-paid-to-possible-interactions
#20
REVIEW
Boris Freidlin, Edward L Korn
Factorial 2 × 2 designs can be used to combine evaluation of two treatments in a single study. The standard analysis approach is based on a factorial analysis that evaluates each treatment by pooling data over the other treatment. This approach relies on the assumption that the effect of each treatment is not substantially affected by the other treatment. In many oncology settings, this no-interaction assumption cannot be adequately supported at the time the trial is designed. In this Commentary, we consider current practices for the design and analysis of factorial trials by performing a survey of factorial treatment trials published in the Journal of the National Cancer Institute, Journal of Clinical Oncology, and the New England Journal of Medicine (2007-2016)...
September 1, 2017: Journal of the National Cancer Institute
keyword
keyword
27183
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"